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Abstract 
Multiple sclerosis (MS), an idiopathic inflammatory demyelinating disease (IIDD), is a major 
cause of neurological disability in young adults. Since early treatment leads to better prognosis, an 
accurate diagnosis at symptoms onset is needed. This retrospective analysis, conducted in Centro 
Hospitalar de São João – EPE, included patients with a focal symptom/signal suggestive of an 
inflammatory/demyelinating process or, alternatively, patients with an asymptomatic 
inflammatory/demyelinating lesion found on magnetic resonance imaging (MRI). Of the 82 
included individuals, clinical definite MS was observed in 25 (30.5%) and clinical isolated 
syndromes in 27 (32.9%). Other diagnosis (36.6%) comprised non-MS IIDDs, systemic 
inflammatory diseases with central nervous system (CNS) involvement, CNS vasculitis, chronic 
relapsing inflammatory optic neuropathy and metabolic disorders. From descriptive analysis, 
monosymptomatic onset predominated for all and, while non-MS group showed a higher mood 
disorders and systemic symptoms prevalence, MS group presented higher fatigue and previous 
neurological events prevalence. Brain MRI findings included T1-hypointense lesions as a major 
MS feature; absent infratentorial lesions and negative enhancement were more frequent in non-MS 
group. On spinal MRI, single lesion, extra-cervical and longitudinally extensive lesions were a 
major finding in non-MS group. On cerebrospinal fluid (CSF) analysis, positive oligoclonal bands 
(OCB) support a MS diagnosis. Statistical analysis revealed a significant relation between MS and 
cranial MRI abnormal findings, T1-hypointensity, enhancement and multiple lesions; while, for 
spinal MRI findings a significant relation was noted for MS and T1-hypointensity and no 
longitudinally extensive lesions. Finally, the strongest relation was found for the presence of CSF-
OCB in MS patients.  
White matter lesions, young adults, differential diagnosis, multiple sclerosis, 
idiopathic inflammatory demyelinating disease, secondary inflammatory disease 
of central nervous system
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Introduction 
An	  acute	  neurologic	  deficit	  in	  young	  adults	  poses	  a	  diagnostic	  challenge	  for	  clinicians	  and	  often	  
non-­‐multiple	  sclerosis	  (non-­‐MS)	  demyelinating	  diseases	  are	  initially	  miss-­‐diagnosed.	  This	  
tendency	  may	  result	  from	  the	  findings	  that	  an	  acute	  neurologic	  deficit	  is	  the	  first	  observed	  
symptom	  in	  approximately	  85%	  of	  young	  adults	  diagnosed	  with	  MS	  [1].	  Notwithstanding,	  a	  
significant	  number	  of	  patients	  with	  clinical	  and	  imaging	  evidence	  of	  demyelinating	  lesion(s)	  –	  
generally	  termed	  clinical	  isolated	  syndrome	  (CIS)	  –	  are	  initially	  (miss)ascribed	  a	  MS	  “label.”	  This	  
represents	  a	  problem	  because	  the	  ability	  to	  make	  an	  accurate	  diagnosis	  as	  early	  as	  possible	  is	  
important	  for	  patient	  management,	  counseling	  and	  optimal	  therapy.	  Here,	  we	  have	  
retrospectively	  analyzed	  a	  cohort	  of	  patients,	  from	  the	  Centro	  Hospitalar	  de	  São	  João	  -­‐	  EPE	  
(Porto,	  Portugal),	  with	  a	  first	  experienced	  neurological	  sign	  or	  symptom	  consistent	  with	  a	  central	  
nervous	  system	  (CNS)	  inflammatory	  demyelinating	  disease	  or,	  alternately,	  patients	  with	  an	  
asymptomatic	  CNS	  white	  matter	  lesion(s),	  incidentally	  found	  on	  a	  neuroaxis	  magnetic	  resonance	  
imaging	  (MRI).	  Epidemiological,	  clinical	  and	  paraclinical	  findings	  were	  reviewed	  in	  order	  to	  
identify	  and	  characterize	  distinct	  subsets	  of	  patients	  in	  the	  setting	  of	  clinical/MRI	  suspected	  MS.	  
The	  work	  followed	  other	  studies	  that	  have	  reviewed	  clinical	  and	  MRI	  presentations	  of	  patients	  
with	  suspected	  MS	  in	  order	  to	  identify	  distinguishing	  features	  that	  may	  suggest	  an	  alternative	  
diagnosis	  (“red	  flags”)	  [2,	  3,	  4].	  
	  
Multiple	  sclerosis	  is	  a	  common	  chronic	  disorder	  of	  the	  CNS	  that	  is	  pathologically	  characterized	  by	  
areas	  of	  inflammatory	  demyelination,	  which,	  over	  time,	  spread	  throughout	  the	  CNS.	  It	  is	  the	  
most	  common	  non-­‐traumatic	  cause	  of	  neurologic	  disability	  in	  Caucasian	  young	  adults,	  affecting	  
predominantly	  women	  between	  20	  and	  45	  years	  of	  age	  [5].	  In	  85%	  of	  patients	  the	  disease	  onset	  
is	  an	  acute	  or	  subacute	  neurological	  attack	  that	  can	  be	  adequately	  explained	  by	  a	  single	  white	  
matter	  lesion	  [1].	  In	  the	  last	  decades,	  different	  MS	  diagnostic	  schemes	  have	  emerged	  indicating	  
that	  clinically	  definite	  MS	  (CDMS)	  diagnosis	  requires	  (i)	  clinical	  and/or	  paraclinical	  evidence	  
displaying	  involvement	  of	  at	  least	  two	  separate	  areas	  of	  the	  CNS	  (“dissemination	  in	  space”	  -­‐	  DIS)	  
and	  (ii)	  the	  occurrence	  of	  two	  different	  lesions	  more	  than	  one	  month	  apart	  (“dissemination	  in	  
time”	  -­‐	  DIT)	  [6-­‐9].	  Regardless	  of	  the	  applied	  criteria,	  MS	  diagnosis	  should	  still	  remain	  clinical	  
evaluation-­‐based	  and,	  when	  facing	  a	  possible	  CIS	  case,	  the	  initial	  step	  must	  be	  the	  exclusion	  of	  a	  
“better	  explanation”	  for	  the	  clinical	  syndrome.	  In	  fact,	  all	  revised	  criteria	  on	  MS	  has	  emphasized	  
that	  MS	  should	  only	  be	  considered	  once	  alternative	  explanations	  for	  the	  clinical	  presentation	  
have	  been	  ruled	  out.	  On	  this,	  it´s	  important	  to	  consider	  that	  a	  wide	  range	  of	  demyelinating	  and	  
non-­‐demyelinating	  pathologies	  may	  mimic	  MS	  in	  presentation,	  namely:	  other,	  non-­‐MS,	  idiopathic	  
inflammatory	  demyelinating	  disease	  (non-­‐MS	  IIDD);	  CNS	  primary	  vasculitis;	  systemic	  
inflammatory	  diseases	  with	  secondary	  CNS	  involvement	  (as	  neurolupus,	  neuro-­‐Beçhet	  disease,	  
neurossarcoidosis,	  SUSAC	  syndrome,	  Sjogren	  syndrome);	  metabolic	  abnormalities	  (vitamin	  B12	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deficiency,	  leukodystrophy	  with	  axonal	  spheroids);	  and,	  infectious,	  neoplastic	  and	  congenital	  
diseases	  [2,	  10,	  11].	  Within	  these	  possibilities,	  epidemiological,	  clinical	  and	  paraclinical	  
consensual	  “red	  flags”	  must	  be	  pursued	  in	  the	  context	  of	  clinically	  suspected	  inflammatory	  
demyelinating	  diseases	  so	  to	  alert	  for	  a	  likely	  non-­‐MS	  diagnostic	  [2].	  The	  diagnostic	  work	  up	  is	  
particularly	  important	  in	  patients	  with	  (i)	  an	  atypical	  neurological	  presentation,	  (ii)	  a	  relapse-­‐
remitting	  clinical	  profile	  or	  (iii)	  lack	  of	  response	  to	  the	  regular	  MS	  treatment	  [12],	  as	  well	  as	  in	  
those	  with	  (iv)	  associated	  systemic	  manifestations,	  (v)	  prominent	  family	  history	  and	  (vi)	  normal	  
results	  in	  MRI,	  cerebrospinal	  fluid	  (CSF)	  and	  evoked	  potential	  studies	  [13].	  In	  order	  to	  exclude	  a	  
spectrum	  of	  diseases	  that	  might	  be	  considered	  in	  the	  differential	  diagnosis	  of	  MS,	  the	  most	  
useful	  tools	  are	  clinical	  history	  and	  physical	  examination,	  MRI	  scanning,	  CSF	  analysis	  (for	  total	  
leucocyte	  count	  and	  cell	  type,	  total	  protein	  and	  albumin,	  glucose,	  serologic	  testing	  for	  infectious	  
agents,	  culture	  and	  CSF	  immunoelectophoresis)	  and	  serum	  analysis.	  	  
	  
In	  this	  study	  the	  aims	  are	  to	  describe	  clinical,	  laboratory	  and	  radiological	  characteristics	  of	  young	  
adult	  patients	  presenting	  with	  a	  CIS	  as	  the	  first	  clinical	  event	  or	  with	  an	  asymptomatic	  white	  
matter	  lesion	  incidentally	  found	  on	  a	  MRI	  ordered	  by	  other,	  non-­‐inflammatory,	  syndromes.	  The	  
association	  between	  these	  characteristics	  and	  the	  final	  diagnosis	  was	  explored	  and,	  finally,	  the	  





The	  study	  was	  conducted	  in	  accordance	  with	  the	  principles	  expressed	  in	  the	  Declaration	  of	  
Helsinki	  and	  approved	  by	  the	  local	  ethical	  committee	  (Comissão	  de	  Ética	  do	  Centro	  Hospitalar	  de	  
São	  João	  –	  EPE).	  All	  medical	  and/or	  research	  professionals	  involved	  in	  the	  study	  were	  asked	  to	  
sign	  a	  responsibility	  document,	  as	  specified	  by	  the	  national	  ethical	  committee.	  
	  
Population sample 
The	  present	  retrospective	  study	  was	  carried	  out	  in	  Neurology	  Service	  of	  the	  Centro	  Hospitalar	  de	  
São	  João	  –	  EPE,	  a	  central	  hospital	  that	  functions	  as	  a	  secondary	  and	  tertiary	  referral	  center.	  The	  
population	  sample	  under	  study	  was	  composed	  of	  young	  adults	  between	  the	  ages	  of	  18	  to	  45	  
years,	  living	  in	  the	  North	  of	  Portugal,	  which	  attended	  the	  Centro	  Hospitalar	  anywhere	  from	  
January	  of	  2007	  until	  September	  of	  2011	  and	  were	  hospitalized	  following	  a	  neurological	  
evaluation	  in	  a	  medical	  office	  or	  emergency	  setting.	  All	  patients	  were	  diagnosed	  with	  a	  
neurological	  signal	  or	  symptom	  consistent	  with	  site	  specific	  inflammatory	  CNS	  demyelination	  or,	  
alternatively,	  with	  a	  white	  matter	  lesion	  on	  MRI	  study.	  Initial	  neurological	  symptoms	  were	  
clinically	  categorized	  as	  monofocal	  or	  multifocal;	  further	  categorization	  of	  monofocal	  symptoms	  
was	  performed	  in	  accordance	  to	  Miller	  DH	  et	  al.	  [2]	  CIS	  features	  as	  (i)	  optic	  nerve,	  (ii)	  brain	  
stem/cerebellum,	  (iii)	  spinal	  cord	  and	  (iv)	  cerebral	  hemispheres	  symptoms	  (Suplemmentary	  Table	  
1).	  Clinical	  isolated	  syndrome	  likelihood	  of	  signaling	  an	  MS	  diagnosis	  was	  not	  evaluated.	  	  
Symptoms	  onset	  were	  categorized	  as	  acute	  or	  progressive.	  	  An	  “acute	  onset”	  is	  here	  defined	  as	  a	  
neurological	  syndrome	  that	  evolves	  over	  a	  48h	  period,	  whereas	  a	  “progressive	  onset”	  as	  one	  that	  
evolves	  over	  a	  48h	  to	  3-­‐week	  period.	  A	  minimum	  24h	  duration	  of	  symptoms	  was	  needed	  for	  
study	  inclusion.	  Following	  these	  initial	  inclusion	  criteria,	  the	  medical	  records	  and	  MRI	  scans	  of	  
119	  patients	  from	  the	  Neurology	  Service	  were	  reviewed.	  A	  total	  of	  37	  patients	  were	  further	  
excluded	  due	  to	  fulfilling	  one	  or	  more	  exclusion	  criteria:	  (i)	  MRI	  scans	  without	  white	  matter	  
lesions,	  (ii)	  CNS	  demyelinating	  disease	  with	  an	  already	  established	  diagnosis,	  (iii)	  cerebrovascular	  
disease	  and	  (iv)	  other	  neurological	  diseases,	  as	  epilepsy	  and	  intracranial	  idiopathic	  hypertension,	  
all	  of	  which	  could	  justify	  the	  lesions	  found	  on	  neuroaxis	  MRI	  scans.	  
	  
Study variables 
Demographic	  and	  clinical	  data	  for	  all	  patients	  were	  entered	  into	  a	  database.	  The	  following	  details	  
were	  recorded	  based	  on	  (and	  in)	  accordance	  to	  a	  standardized	  hospital	  discharge	  note	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performed	  by	  the	  assistant	  clinician:	  (i)	  basic	  demographic	  data	  [sex,	  ethnicity,	  date	  of	  birth	  and	  
age	  at	  current	  (demyelinating)	  clinical	  event];	  (ii)	  presenting	  demyelinating	  symptoms/signs	  and	  
associated	  systemic	  symptoms;	  (iii)	  symptoms	  onset;	  (iv)	  personal	  history	  of	  previous	  attacks,	  
recent	  infection	  (last	  three	  months)	  or	  vaccination	  (last	  six	  months),	  past	  symptoms	  suggestive	  of	  
autoimmunity/systemic	  disease;	  (v)	  current	  medication	  and	  (vi)	  family	  history	  of	  CNS	  
demyelinating	  diseases,	  neurodegenerative	  disorders,	  brain	  neoplasms,	  cerebrovascular	  diseases	  
in	  young	  adults	  and	  autoimmunity.	  A	  neurological	  examination	  was	  performed	  for	  all	  subjects	  at	  
the	  time	  of	  hospitalization	  and	  at	  the	  time	  of	  discharge.	  Paraclinical	  data	  was	  also	  gathered	  from	  
clinical	  records,	  including	  (i)	  brain	  and/or	  spinal	  cord	  MRI	  findings,	  (ii)	  electrophysiological	  
findings	  [visual	  evoked	  potentials	  (VEP),	  brain	  auditory	  evoked	  potentials	  (BAEP),	  somatosensory	  
evoked	  potentials	  (SSEP)],	  (iii)	  laboratory	  tests,	  CSF,	  blood	  and	  sera	  analysis	  included	  and	  (iv)	  
chest	  x-­‐ray	  (CXR)	  or	  other	  performed	  studies	  according	  to	  their	  clinical	  relevance.	  The	  final	  
diagnosis	  was	  established	  and	  registered	  by	  the	  expert	  opinion	  of	  the	  assistant	  clinician,	  
according	  to	  the	  established	  criteria	  at	  the	  time	  of	  hospitalization	  (Supplementary	  Table	  2).	  	  
	  
MRI scanning 
Neuroaxis	  MRI	  scans	  were	  performed	  in	  all	  patients,	  in	  the	  hospital	  setting	  or	  in	  ambulatory.	  
Conventional	  MRI	  protocols	  were	  used:	  T1	  with	  and	  without	  gadolinium	  enhancement,	  T2,	  fluid	  
attenuated	  inversion	  recovery	  (FLAIR)	  in	  brain	  MRI;	  T1	  with	  and	  without	  gadolinium	  
enhancement	  and	  T2	  in	  spinal	  cord	  MRI.	  All	  MRI	  scans	  were	  analyzed	  by	  an	  experienced	  
neuroradiologist	  and	  for	  the	  present	  study	  the	  report	  was	  reviewed	  for	  specific	  details	  as	  to	  the	  
(i)	  number,	  (ii)	  shape,	  (iii)	  location,	  (iv)	  size,	  (v)	  signal	  characteristics	  of	  the	  lesions	  and	  (vi)	  lesions’	  
enhancement	  after	  gadolinium.	  Whenever	  applicable,	  these	  details	  were	  entered	  into	  the	  
database.	  
	  
Blood and cerebrospinal fluid assessments 
Serum	  and	  CSF	  samples	  were	  analyzed	  for	  the	  presence	  of	  oligoclonal	  bands	  (OCBs)	  and	  IgG	  
index	  to	  identify	  systemic	  or	  neurologic	  inflammatory	  disease.	  Samples	  were	  classified	  according	  
to	  whether	  the	  patients	  had	  evidence	  of	  intrathecal	  IgG	  synthesis,	  evidence	  of	  a	  systemic	  
oligoclonal	  response	  with	  matched	  bands	  in	  the	  serum	  and	  CSF	  or	  no	  evidence	  of	  an	  intrathecal	  
neither	  systemic	  oligoclonal	  IgG	  response.	  Additional	  measurements	  regarding	  standard	  CSF	  and	  
blood	  analysis	  were	  also	  performed,	  namely:	  (i)	  glucose,	  proteins	  and	  lactate	  CSF	  content;	  (ii)	  
microbiological	  CSF	  and	  blood	  analysis;	  (iii)	  immunological	  studies,	  including	  antinuclear	  
antibodies	  (ANAs:	  anti	  DNSds	  included),	  anti-­‐neutrophil	  cytoplasmic	  antibodies	  (ANCAs:	  ANCA	  
PR3	  and	  ANCA	  MPO	  included),	  anti-­‐phospholipid	  antibodies	  [aPL:	  anti-­‐β2	  glicoprotein	  I	  (anti-­‐
β2GPI)	  IgM	  and	  IgG,	  anticardiolipin	  antibodies	  (aCL)	  IgM	  and	  IgG	  included],	  anti-­‐extractable	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nuclear	  antigens	  (ENAs:	  anti-­‐Jo	  1,	  anti-­‐RNP,	  anti-­‐SCL70,	  anti-­‐Sm,	  anti-­‐SSa	  and	  anti-­‐SSb	  included)	  
and	  serum	  reumatoid	  factor	  (RF);	  (iv)	  hematocrit	  and	  biochemistry	  blood	  analysis;	  (v)	  folic	  acid	  
(vitamin	  B9)	  and	  cobalamin	  (vitamin	  B12)	  assays	  and	  (vi)	  other	  measurements	  performed	  
according	  to	  individual-­‐specific	  clinical	  relevance.	  
	  
Statistical analysis 
Descriptive	  analysis	  and	  chi-­‐square	  test	  (based	  on	  crosstabs	  and	  used	  to	  test	  interdependency	  of	  




The	  study	  included	  a	  total	  of	  119	  patients,	  of	  whom	  37	  were	  excluded	  as	  they	  fulfilled	  one	  or	  
more	  of	  the	  exclusion	  criteria.	  Of	  the	  excluded	  patients,	  26	  (70.3%)	  were	  female	  and	  11	  (29.7%)	  
were	  male,	  with	  an	  average	  age	  of	  28.9±7.1	  (18-­‐41)	  and	  33.1±7.5	  (21-­‐42)	  years	  old,	  respectively.	  
The	  most	  frequent	  diagnoses	  of	  this	  group	  were	  inflammatory	  diseases	  without	  white	  matter	  
lesions	  	  [including	  idiopathic	  and	  systemic	  disease-­‐associated	  optic	  neuritis	  (Sjogren’s	  syndrome,	  
Behçet	  disease	  and	  Cogan’s	  syndrome)]	  and	  patients	  with	  previous	  MS	  diagnosis	  (41%).	  These	  
were	  followed	  in	  frequency	  by	  vascular	  (cerebrovascular	  disease,	  ischemic	  neuropathy	  and	  
vasculo-­‐neurobehçet)	  (19%),	  ophthalmological	  (16%),	  infectious	  [Epstein-­‐Barr	  Virus	  (EBV),	  
Treponema	  pallidum	  and	  Brucella	  infections	  included]	  (8%),	  other	  neurological	  (epilepsy	  and	  
idiopathic	  intracranial	  hypertension	  included)	  (8%),	  toxic/metabolic	  (5%)	  and	  degenerative	  
(pseudoxantoma	  elasticum)	  (3%)	  disorders,	  all	  of	  which	  without	  inflammatory/demyelinating	  
lesions	  described	  on	  neuroaxis	  MRI	  report.	  
Apart	  of	  the	  excluded	  patients,	  the	  study	  included	  a	  total	  of	  82	  individuals,	  53	  (64.6%)	  females	  
and	  29	  (35.4%)	  males,	  with	  an	  average	  age	  of	  30.5±7.1	  (19-­‐42)	  and	  31.3±6.1	  (21-­‐44)	  years,	  
respectively.	  The	  majority	  of	  the	  patients	  sought	  first	  medical	  care	  within	  the	  first	  seven	  days	  of	  
symptom	  development,	  with	  a	  progressive	  onset	  described	  in	  57.3%	  of	  patients,	  acute	  in	  39.0%	  
and	  non-­‐determined	  in	  3.7%.	  Monofocal	  presentation	  was	  observed	  in	  85.3%	  of	  the	  patients,	  
with	  spinal	  cord	  and	  optic	  nerve	  syndromes	  being	  the	  most	  frequent	  (28.0%	  and	  24.4%,	  
respectively),	  followed	  by	  cerebral	  hemispheres	  and	  brain	  stem/cerebellum	  (22.0%	  and	  11.0%,	  
respectively);	  multifocal	  symptoms	  were	  observed	  in	  9.8%.	  A	  minor	  subset	  of	  patients	  (4.9%)	  
presented	  a	  non-­‐inflammatory	  clinical	  syndrome,	  although	  the	  MRIs	  from	  these	  patients	  showed	  
lesions	  that	  might	  have	  an	  inflammatory/demyelinating	  etiology	  [this	  is	  known	  by	  radiological	  
isolated	  syndromes	  (RIS)]	  (Table	  1).	  
From	  total	  patient	  records,	  81	  underwent	  brain	  MRI,	  with	  white	  matter	  lesions	  being	  described	  in	  
76	  (93.8%)	  individuals,	  and	  58	  patients	  had	  spinal	  cord	  MRI,	  with	  40	  (69.0%)	  reporting	  white	  
matter	  lesions.	  From	  patients	  with	  an	  abnormal	  brain	  MRI,	  73	  (96.1%)	  presented	  multiple	  and	  3	  
(3.9%)	  a	  single	  lesion.	  From	  the	  40	  patients	  with	  spinal	  cord	  demyelination	  19	  (47.5%)	  had	  
multiple	  lesions,	  20	  (50.0%)	  a	  single	  lesion	  and	  no	  available	  data	  was	  available	  for	  one	  (2.5%).	  
Longitudinally	  extensive	  lesions	  (LELs,	  extending	  along	  three	  or	  more	  contiguous	  vertebral	  
segments)	  were	  described	  in	  6	  of	  the	  scans	  (15.0%).	  Oligoclonal	  bands	  in	  CSF	  and	  serum	  were	  
available	  for	  76	  patients:	  positive	  CSF-­‐OCBs	  were	  described	  in	  56	  (60.5%)	  with	  only	  one	  patient	  
displaying	  simultaneous	  serum-­‐OCBs.	  IgG	  index	  was	  also	  available	  for	  59	  individuals	  and,	  for	  this	  
cohort,	  average	  value	  was	  0.92	  ±	  0.50	  (0.2-­‐2.9).	  Of	  the	  82	  patients,	  VEP	  were	  studied	  in	  63,	  BAEP	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in	  4	  and	  SSEP	  in	  30	  patients.	  Abnormal	  results	  were	  detected	  in	  27	  (42.9%),	  2	  (50.0%)	  and	  6	  
(20.0%)	  patients,	  respectively.	  
	  
Final diagnosis 
When	  the	  cohort	  was	  analyzed	  attending	  to	  the	  final	  diagnosis,	  an	  IIDD	  was	  established	  for	  71	  
patients	  (71/82;	  86.6%),	  45	  females	  (63.4%)	  and	  26	  males	  (36.6%)	  (female	  to	  male	  ratio	  of	  
1.73:1),	  with	  an	  average	  age	  of	  31.1±6.7	  (19-­‐44)	  years	  old.	  From	  this	  major	  group,	  52	  patients	  
were	  diagnosed	  with	  MS	  IIDD,	  namely	  CDMS	  (25/82;	  30.5%)	  and	  CIS	  (27/82;	  32.9%);	  the	  
remaining	  19	  were	  diagnosed	  with	  non-­‐MS	  IIDD,	  including	  RIS	  (4/82;	  4.9%),	  acute	  disseminated	  
encephalomyelitis	  (ADEM;	  3/82;	  3.7%)	  and	  other	  IIDDs	  (12/82;	  14.6%).	  Radiological	  isolated	  
syndromes	  encompassed	  4	  patients	  who	  had	  evidence	  of	  CNS	  inflammatory	  demyelinating	  
lesions	  on	  brain	  MRI	  scans	  performed	  by	  clinical	  conditions	  not	  typically	  neuro-­‐inflammatory	  in	  
nature	  (migraine,	  Todd´s	  paresis,	  somatization	  disorder	  and	  inflammatory	  orbital	  symptoms).	  
Other	  IIDDs	  included	  6	  acute	  myelitis	  (3	  idiopathic	  and	  3	  parainfectious),	  4	  idiopathic	  optic	  
neuritis	  and	  2	  IIDDs	  cases	  in	  whom	  a	  definite	  diagnose	  was	  not	  performed	  (NA	  IIDD)	  (Fig.	  1).	  
From	  the	  remaining	  11	  individuals,	  4	  (4/82;	  4.9%)	  were	  discharged	  with	  a	  CNS	  inflammatory	  
disease,	  but	  an	  etiological	  diagnose	  was	  not	  performed	  (NA).	  A	  miscellaneous	  group	  of	  disorders	  
comprised	  the	  remaining	  7	  patients	  (7/82;	  8.5%)	  who	  were	  assigned	  a	  non-­‐IIDD:	  3	  diagnosis	  of	  
systemic	  inflammatory	  disease	  with	  CNS	  involvement	  (neurossarcoidosis,	  neurolupus	  and	  
neurobeçhet	  diseases)(3/82;	  3.7%),	  one	  of	  primary	  CNS	  vasculitis	  (1/82;	  1.2%),	  one	  of	  probable	  
chronic	  relapsing	  inflammatory	  optic	  neuropathy	  (CRION;	  1/82;	  1.2%),	  and	  2	  (male)	  patients	  with	  
a	  metabolic	  disorder	  (one	  leukodystrophy	  with	  axonal	  spheroids	  and	  one	  subacute	  combined	  
degeneration	  of	  spinal	  cord)(2/82;	  2.4%)	  (Fig.	  1).	  
	  
“Non-MS” Group Characterization 
The	  “non-­‐MS”	  group	  [patients	  with	  non-­‐MS	  IIDD,	  non-­‐IIDD	  and	  cases	  without	  a	  definite	  diagnose	  
(NA)]	  was	  comprised	  of	  30	  patients,	  with	  an	  average	  age	  of	  30.8±7.0	  years	  old	  (20-­‐44)	  
(Supplementary	  Table	  3).	  The	  most	  frequent	  clinical	  presentation	  included	  optic	  nerve	  (33.3%)	  or	  
spinal	  cord	  (30.0%)	  symptoms,	  with	  one	  (3.3%)	  patient	  presenting	  a	  clinical	  multifocal	  
presentation.	  Symptoms	  onset	  was	  progressive	  in	  16	  (53.3%)	  individuals	  (Table	  1).	  Clinical	  
records	  showed,	  as	  other	  presenting	  symptoms,	  2	  (6.7%)	  patients	  with	  fatigue	  (Fig.	  2a),	  8	  (26.7%)	  
with	  past	  or	  present	  history	  of	  mood	  disorders	  (Fig.	  2b),	  9	  (30.0%)	  with	  previous	  systemic	  
symptoms	  (infectious	  symptoms	  in	  last	  three	  months,	  reumathological	  disease,	  oral	  and/or	  
genital	  ulcers	  and	  rash	  included)	  (Fig.	  2c),	  and	  8	  (26.7%)	  patients	  with	  previous	  neurological	  
events.	  A	  positive	  family	  history	  of	  vascular,	  neurological	  and/or	  reumathological	  disease	  was	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reported	  by	  9	  (30.0%)	  patients	  (Fig.	  2d).	  Imaging	  evidence	  of	  brain	  lesions	  was	  detected	  in	  24	  
(82.8%)	  of	  the	  29	  patients	  that	  performed	  a	  brain	  MRI.	  Specifically,	  in	  these,	  a	  single	  T2	  
hyperintensity	  was	  detected	  in	  3	  (12.5%)	  patients,	  while	  21	  (87.5%)	  had	  multiple	  lesions.	  Isolated	  
supratentorial	  lesions	  were	  the	  most	  frequent	  finding	  (15/24;	  62.5%),	  followed	  by	  supratentorial	  
and	  infratentorial	  lesions	  (7/24;	  29.2%),	  and	  by	  isolated	  optic	  nerve	  lesions	  (2/24;	  8.3%)	  (Fig.	  3a).	  
In	  respect	  to	  the	  T1	  signal,	  lesions	  were	  T1	  hypointense	  in	  6	  (25.0%)	  patients	  and	  enhanced	  after	  
gadolinium	  in	  the	  same	  frequency	  (Fig.	  3b	  and	  3c).	  For	  spinal	  cord	  MRI,	  abnormal	  results	  were	  
described	  in	  12	  (66.7%)	  out	  of	  the	  18	  screened	  patients.	  Findings	  included	  a	  single	  T2	  
hyperintense	  lesion	  in	  9	  (75.0%)	  patients,	  with	  the	  remaining	  3	  (25.0%)	  having	  multiple	  lesions	  
with	  same	  signal	  characteristics	  (Fig.	  4b).	  Cervical	  levels	  were	  the	  most	  affected	  (5/12;	  41.7%),	  
followed	  by	  dorsal	  (3/12;	  25.0%)	  and	  cervical	  plus	  dorsal	  levels	  (2/12;	  16.7%)	  (Fig.	  4a).	  
Longitudinally	  extensive	  lesions	  were	  found	  in	  5/12	  (41.7%)	  individuals	  (Fig.	  4c),	  cord	  swelling	  in	  
2/12	  (16.7%)	  and	  positive	  enhancement	  in	  6/12	  (50.0%).	  Visual	  evoked	  potentials	  (VEP)	  were	  
abnormal	  in	  7/19	  (36.8%)	  of	  patients	  who	  performed	  this	  electrophysiological	  exam;	  9	  patients	  
performed	  somatosensory	  (SSEP)	  and	  2	  auditory	  (AEP)	  evoked	  potentials,	  with	  normal	  results	  in	  
both.	  Available	  laboratory	  tests	  (CSF	  and	  serum),	  showed	  positive	  CSF-­‐OCBs	  in	  6	  out	  of	  26	  
patients	  (23.1%)	  and	  an	  IgG	  index	  greater	  than	  0.6	  was	  observed	  in	  7	  out	  of	  21	  patients	  
(0.62±0.27,	  0.30-­‐1.40).	  None	  of	  these	  individuals	  had	  matched	  OCBs	  in	  serum.	  Average	  CSF-­‐count	  
of	  cells	  was	  21.9±51.7	  (0-­‐230µL)	  and	  average	  CSF-­‐protein	  content	  was	  0.52±0.18	  (0.10-­‐1.04g/L).	  
Microbiological	  assays	  were	  positive	  in	  6/26	  (23.1%)	  patients,	  with	  positive	  CSF	  results	  for	  
cytomegalovirus	  (CMV;	  one	  patient	  by	  PCR),	  EBV	  (one	  patient	  by	  PCR),	  enterovirus	  (2	  patients	  by	  
PCR),	  human	  herpes	  virus	  6	  (HHV6;	  one	  patient	  by	  PCR)	  and	  Mycoplasma	  pneumonia	  (one	  
patient	  by	  PCR).	  Five	  out	  of	  30	  patients	  (16.7%)	  had	  a	  positive	  immunological	  study:	  ANAs	  in	  3,	  
anti-­‐β2GPI	  in	  one,	  anti-­‐PR3	  and	  anti-­‐β2GPI	  in	  another	  one	  patient.	  
	  
“MS” Group Characterization 
The	  group	  comprised	  52	  subjects	  of	  which	  27	  CIS	  and	  25	  CDMS,	  with	  an	  average	  age	  of	  30.8±6.6	  
(19-­‐41)	  year	  old	  (Supplementary	  Table	  4).	  The	  most	  frequent	  presenting	  symptoms	  were	  
monofocal	  and	  clinically	  restricted	  to	  the	  spinal	  cord	  (14/52;	  26.9%),	  followed	  by	  cerebral	  
hemispheres	  (13/52;	  25.0%),	  optic	  nerve	  (10/52;	  19.2%)	  and	  brain	  stem/cerebellum	  (8/52;	  
15.4%)	  symptoms.	  A	  multifocal	  presentation	  was	  recorded	  in	  7	  (13.5%)	  of	  the	  patients	  and	  a	  
progressive	  presentation	  was	  the	  most	  frequent	  onset	  (31/52;	  59.6%)	  (Table	  1).	  Clinical	  interview	  
records	  included,	  as	  other	  presenting	  symptoms	  or	  past	  medical	  history,	  8	  (15.4%)	  patients	  with	  
fatigue	  (Fig.	  2a),	  7	  (13.5%)	  with	  history	  of	  mood	  disorders	  (Fig.	  2b),	  11	  (21.2%)	  with	  systemic	  
symptoms	  (mostly	  of	  these	  having	  a	  previous	  infection	  in	  the	  last	  3	  months,	  but	  also	  some	  
experiencing	  past	  or	  present	  reumathological	  symptoms,	  oral	  and/or	  genital	  ulcers,	  SICCA	  
symptoms	  and	  rash)	  (Fig.	  2c),	  and	  23	  (44.2%)	  individuals	  with	  previous	  neurological	  events.	  A	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positive	  family	  history	  of	  vascular,	  neurological	  and/or	  reumathological	  disease	  was	  reported	  by	  
7	  patients	  (13.5%)	  (Fig.	  2d).	  Imaging	  evidence	  of	  demyelinating	  disease	  was	  detected	  in	  the	  brain	  
MRI	  scans	  of	  all	  patients,	  with	  dissemination	  in	  space	  being	  verified	  in	  all.	  The	  most	  frequent	  
neuroradiological	  findings	  were	  T2/FLAIR	  hyperintense	  and	  T1	  hypointense	  (33/52;	  63.5%)	  
multifocal	  lesions,	  with	  localization	  in	  both	  supratentorial	  and	  infratentorial	  areas	  in	  71.2%	  
(37/52)	  of	  patients	  (Fig.	  3a),	  with	  positive	  enhancement	  after	  gadolinium	  being	  described	  in	  
28/52	  (53.8%)	  (Fig.	  3c).	  Other	  lesion	  locations	  included	  supratentorial	  only	  (12/52;	  23.1%)	  and	  
simultaneous	  supratentorial,	  infratentorial	  and	  optic	  nerve	  (3/52;	  5.8%)	  (Fig.	  3a).	  A	  spinal	  cord	  
MRI	  was	  obtained	  in	  40	  patients,	  with	  abnormal	  results	  recorded	  in	  28	  (70%).	  Findings	  included	  
T2	  hyperintense	  and	  T1	  hypointense	  signal	  lesions	  in	  8	  (28.6%).	  Multiple	  lesions	  were	  verified	  in	  
16/28	  (57.1%)	  of	  the	  scans	  (Fig.	  4b),	  with	  cervical	  levels	  being	  the	  most	  affected	  (15/28;	  53.6%),	  
followed	  in	  frequency	  by	  cervical	  and	  dorsal	  (8/28;	  28.6%)	  and	  dorsal	  (3/28;	  10.7%)	  levels	  (Fig.	  
4a);	  longitudinally	  extensive	  lesion	  was	  described	  in	  one	  (3.6%)	  patient	  (Fig.	  4c),	  cord	  swelling	  in	  6	  
(21.4%)	  and	  positive	  enhancement	  in	  13	  of	  available	  results	  (13/28;	  46.4%).	  VEP	  was	  abnormal	  in	  
20/44	  (45.5%)	  of	  patients;	  SSEP	  anomalous	  in	  6/21	  (28.6%)	  and	  PEA	  in	  2/2	  (100.0%).	  The	  
laboratory	  tests	  performed	  in	  these	  patients	  and	  accessible	  for	  data	  analysis,	  displayed	  positive	  
CSF-­‐OCBs	  in	  40	  out	  of	  50	  patients	  (80.0%)	  and	  an	  IgG	  index	  greater	  than	  0.6	  in	  31	  out	  of	  38	  
patients	  (1.09±0.52,	  0.20-­‐2.90).	  One	  of	  these	  patients	  had	  matched	  OCBs	  in	  serum,	  however	  
electrophoresis	  analysis	  showed	  a	  lower	  number	  of	  bands.	  Within	  this	  group,	  OCBs	  were	  also	  
analysed	  by	  gender	  and	  by	  age:	  positive	  CSF	  bands	  were	  detected	  in	  84.4%	  of	  female	  MS	  patients	  
versus	  72.2%	  of	  male	  MS	  patients	  and	  in	  81.1%	  of	  MS	  patients	  less	  than	  30	  years	  of	  age	  versus	  
78.6%	  of	  patients	  with	  30	  or	  more	  years.	  Average	  CSF-­‐count	  of	  cells	  was	  9.6±14.6	  (0-­‐90µL)	  and	  
average	  CSF-­‐protein	  content	  was	  0.57±0.34	  (0.10-­‐2.47g/L).	  A	  positive	  microbiological	  assay	  was	  
positive	  in	  2/51	  (3.9%)	  patients,	  with	  positive	  CSF	  results	  for	  enterovirus	  (one	  patient	  by	  PCR)	  and	  
Mycoplasma	  pneumonia	  (one	  patient	  by	  PCR).	  Seven	  out	  of	  52	  patients	  (13.5%)	  had	  a	  positive	  
immunological	  study:	  ANAs	  and	  anti-­‐	  SSa	  in	  one,	  anti-­‐β2GPI	  in	  5,	  β2GPI	  and	  aCL	  in	  another	  one	  
patient.	  
	  
From	  the	  descriptive	  analysis	  the	  more	  relevant	  parameters	  were	  analyzed	  by	  chi-­‐square	  tests.	  
These	  included:	  i)	  clinical	  parameters	  (fatigue,	  mood	  disorders,	  systemic	  symptoms	  and	  familiar	  
history);	  ii)	  biochemical	  parameters	  (CSF-­‐OCBs	  and	  auto-­‐	  antibodies);	  and	  iii)	  MRI	  findings	  [cranial	  
(parameters:	  normal	  or	  abnormal,	  number	  of	  lesions,	  signal	  characteristics	  of	  the	  lesions	  and	  
enhancement)	  and	  spinal	  cord	  (parameters:	  normal	  or	  abnormal,	  number	  of	  lesions,	  
longitudinally	  extensive	  lesions,	  signal	  characteristics	  of	  the	  lesions	  and	  enhancement)].	  No	  
significant	  relation	  between	  the	  clinical	  parameters	  and	  clinical	  diagnosis	  (MS	  or	  non-­‐MS)	  was	  
noted.	  For	  the	  biochemical	  parameters,	  a	  significant	  relation	  was	  found	  between	  MS	  and	  CSF-­‐
OCBs	  (p<0.001).	  Regarding	  the	  MRI	  findings,	  for	  the	  cranial	  parameters	  the	  following	  significant	  
relations	  were	  identified	  for	  the	  MS	  group	  with:	  abnormal	  findings	  (p=0.005),	  T1	  hypointense	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lesion	  (p=0.003),	  and	  positive	  lesion	  enhancement	  (p=0.026).	  For	  the	  same	  parameter,	  regarding	  
the	  non-­‐MS	  group	  a	  relation	  was	  found	  for	  single	  lesion	  (p=0.029),	  meaning	  that	  multiple	  lesions	  
were	  related	  with	  the	  MS	  group.	  Finally,	  for	  the	  spinal	  MRI	  observations,	  a	  relation	  was	  found	  for	  




The	  aim	  of	  this	  retrospective	  study	  was	  to	  systematically	  describe	  and	  analyze	  clinical,	  imaging,	  
CSF	  and	  blood	  findings	  of	  a	  cohort	  of	  patients	  who	  entered	  the	  Neurology	  Department	  with	  a	  
focal	  symptom/signal	  suggestive	  of	  an	  inflammatory	  demyelinating	  process	  or,	  alternately,	  
patients	  with	  an	  asymptomatic	  inflammatory	  demyelinating	  lesion	  incidentally	  found	  on	  a	  MRI	  
scan	  performed	  for	  other	  neurological	  symptoms,	  atypical	  for	  a	  CNS	  demyelinating	  process.	  
Regarding	  final	  diagnosis,	  the	  present	  data	  analysis	  demonstrated	  that	  52/82	  (63.4%)	  patients	  
had	  MS	  diagnosis.	  This	  incidence	  is	  relatively	  high	  when	  comparing	  with	  other	  published	  
retrospective/prospective	  studies,	  namely	  by	  Kelly	  et	  al.	  (2011)	  and	  Carmosimo	  et	  al.	  (2005),	  
which	  showed	  a	  cohort	  incidence	  of	  MS/CIS	  of	  119/244	  (49.0%)	  and	  94/281	  (33%),	  respectively	  
[3,	  4].	  However,	  both	  studies	  included	  a	  larger	  number	  of	  adult	  patients	  of	  all	  ages.	  
	  
Clinical onset 
An	  abrupt	  clinical	  onset	  is	  considered	  by	  the	  European	  MAGNIMS	  group	  as	  a	  minor	  “red	  flag”,	  
meaning	  that,	  while	  facing	  a	  CIS	  case	  with	  such	  onset,	  the	  clinician	  should	  seek	  also	  for	  other,	  
non-­‐MS	  causes	  that	  might	  be	  possible	  explanations	  for	  that	  symptoms.	  However,	  of	  note,	  our	  
study	  design	  initially	  excluded	  patients	  with	  focal	  symptoms	  of	  a	  definitive	  vascular	  origin,	  the	  
major	  differential	  diagnosis	  in	  this	  hypothetical	  setting.	  Even	  though	  our	  MS	  cohort	  is	  in	  
accordance	  to	  this,	  as	  a	  small	  group	  of	  patients	  (38.5%)	  presented	  an	  acute	  onset.	  
Here,	  clinical	  symptoms	  were	  categorized	  according	  to	  their	  anatomical	  correlation	  (and	  not	  by	  
their	  likelihood	  of	  signaling	  an	  MS	  diagnosis)	  and	  mono/multifocal	  categorization	  was	  based	  
solely	  on	  patients’	  reported	  symptoms.	  The	  MS	  population	  here	  studied	  presented	  mostly	  with	  a	  
monofocal	  picture:	  spinal	  cord	  symptoms	  were	  the	  most	  frequent	  finding	  (14/52;	  26.9%)	  (e.g.	  
numbness,	  (a)symmetrical	  progressive	  spastic	  paraplegia,	  segmental	  loss	  of	  sensation,	  
progressive	  sensory	  ataxia,	  urinary	  symptoms)	  followed,	  similarly	  in	  frequency,	  by	  cerebral	  
hemispheres	  (hemiparesis,	  quadrantanopsia,	  cognitive	  function),	  optic	  nerve	  (unilateral	  optic	  
neuritis,	  pain	  on	  eye	  movement,	  visual	  blurring,	  no	  light	  perception)	  and	  brain	  stem/cerebellum	  
(internuclear	  ophthalmoplegia,	  cranial	  nerves	  palsies)	  symptoms.	  These	  findings	  are	  in	  
accordance	  with	  reports	  that	  describe	  an	  isolated	  optic	  nerve	  symptoms	  incidence	  of	  20.1%	  and	  
18.8%	  and	  of	  an	  isolated	  brainstem	  dysfunction	  of	  14.7%	  and	  25.0%	  [14,	  15].	  In	  fact,	  altogether,	  
only	  a	  small	  percentage	  of	  MS	  patients	  showed	  a	  multifocal	  symptoms	  onset	  (7/52;	  13.5%);	  this	  
finding	  is	  also	  similar	  to	  other	  studies	  which	  report	  a	  14.2%	  and	  29.4%	  (based	  on	  symptoms	  and	  
signs)	  prevalences	  [15,	  14].	  A	  multisymptomatic/multifocal	  presentation	  was	  a	  rare	  condition	  in	  
our	  cohort,	  but	  this	  should	  be	  taken	  with	  some	  caution:	  as	  expected	  by	  the	  diagnostic	  criteria	  
(which	  includes	  DIS),	  and	  by	  the	  well	  known	  course	  of	  the	  disease,	  the	  MS	  patients	  suffer	  from	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progressive	  neurological	  deficits.	  So,	  as	  it	  is	  recognized	  by	  the	  MAGNIMS	  group,	  persistently	  
monofocal	  manifestations	  should	  be	  regarded	  as	  a	  major	  clinical	  “red	  flag”	  finding	  suggestive	  of	  
an	  alternative	  diagnosis.	  This	  study,	  because	  it	  is	  a	  transversal	  analysis,	  was	  not	  able	  to	  account	  
for	  such	  possible	  findings.	  
	  
Other presenting systemic symptoms, past medical history and 
family history 
When	  analyzing	  the	  MS	  patients,	  non-­‐focal	  and	  systemic	  symptoms	  are	  also	  of	  clinical	  relevance	  
and,	  for	  that	  reason,	  patients	  were	  inquired	  about	  fatigue,	  mood	  disorders,	  recent	  infection	  
(previous	  3	  months),	  recent	  vaccination	  (previous	  6	  months),	  genital/oral	  ulcers,	  reumathologic	  
symptoms	  (arthritis,	  polyarthalgias,	  myalgias	  included),	  SICCA	  symptoms	  and	  skin	  rash,	  some	  of	  
which	  constitute	  clinical	  “red	  flags”.	  In	  our	  cohort,	  the	  MS	  group	  presented	  a	  higher	  prevalence	  in	  
fatigue	  and	  previous	  neurological	  events,	  while	  the	  non-­‐MS	  group	  showed	  a	  higher	  prevalence	  in	  
mood	  disorders	  and	  systemic	  symptoms	  (Fig.	  3).	  Considering	  fatigue	  and	  mood	  disorders,	  these	  
are	  well	  recognized	  symptoms	  in	  MS	  and	  it´s	  not	  uncommon	  to	  evaluate	  these	  symptoms	  at	  the	  
same	  time	  [16,	  17].	  In	  the	  MS	  group,	  the	  prevalence	  of	  these	  2	  symptoms	  was	  similar	  which	  
could	  suggest	  an	  association	  between	  them,	  however,	  only	  one	  patient	  within	  this	  group	  actually	  
presented	  both	  symptoms	  simultaneously.	  Also	  important	  is	  the	  prevalence	  of	  fatigue	  in	  the	  MS	  
population,	  which	  is	  reported	  to	  have	  an	  incidence	  of	  10%	  to	  20%	  at	  MS	  disease	  onset	  [18].	  
Previous/concurrent	  infection	  is	  also	  important	  in	  the	  patients’	  diagnosis	  as	  it	  can	  suggest	  an	  
ethiological	  process	  (e.	  g.	  parainfectious).	  Besides,	  a	  transient	  emergence	  or	  worsening	  of	  
neurological	  symptoms,	  chronologically	  related	  to	  a	  change	  in	  body	  temperature	  as	  a	  febrile	  
illness	  for	  instance,	  is	  highly	  suggestive	  of	  a	  demyelinating	  disorder	  (Uhthoff’s	  phenomenon)	  [5].	  
Here,	  a	  higher	  prevalence	  of	  previous	  infection	  was	  found	  in	  the	  non-­‐MS	  patients	  with	  ADEM	  (3	  
out	  of	  3	  diagnosed	  patients),	  acute	  myelitis	  (one	  out	  of	  6)	  and	  optic	  neuritis	  (one	  out	  of	  4).	  This	  
agrees	  with	  the	  well	  described	  abrupt	  onset	  of	  neurological	  symptoms	  and	  signs	  within	  days	  to	  
weeks	  after	  a	  viral	  infection	  or	  immunization	  that	  occurs	  in	  ADEM	  and	  parainfectious	  
monossimptomatic	  IIDDs	  [19].	  A	  positive	  family	  history	  of	  CNS	  demyelinating	  diseases,	  
neurodegenerative	  disorders,	  brain	  neoplasms,	  cerebrovascular	  disease	  in	  young	  adults	  and/or	  
autoimmunity	  was	  also	  more	  frequent	  in	  the	  non-­‐MS	  compared	  to	  the	  MS	  group.	  The	  neurolupus	  
case	  should	  be	  here	  emphasized,	  as	  a	  patient’s	  sister	  was	  also	  diagnosed	  with	  systemic	  lupus	  
erythematous	  (SLE),	  whereas	  only	  one	  patient	  from	  the	  MS	  group	  presented	  a	  family	  case	  of	  MS.	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Brain and spinal cord MRI findings 
Magnetic	  resonance	  imaging	  is	  without	  a	  doubt	  an	  important	  tool	  in	  the	  diagnostic	  pathway	  for	  
symptoms	  consistent	  with	  inflammatory	  demyelinating	  disease.	  It	  allows,	  for	  instance,	  the	  initial	  
exclusion	  of	  some	  non-­‐demyelinating	  causes	  that	  might	  mimic	  those	  symptoms	  and,	  once	  
demyelination	  is	  confirmed,	  for	  the	  characterization	  of	  the	  process,	  further	  leading	  to	  a	  
specific/definitive	  diagnostic	  [20].	  Some	  paradigmatic	  cases	  were	  present	  in	  our	  cohort	  
(leukodystrophy,	  subacute	  combined	  degeneration	  of	  spinal	  cord,	  primary	  CNS	  vasculitis)	  and,	  in	  
this	  context,	  an	  imaging	  characterization	  of	  the	  studied	  population	  was	  performed.	  	  
Adding	  to	  the	  value	  of	  abnormal	  imaging	  findings	  in	  MS	  diagnosis,	  only	  30%	  of	  studied	  MS	  
population	  presented	  no	  spinal	  cord	  lesions,	  with	  a	  similar	  incidence	  in	  the	  non-­‐MS	  group.	  The	  
latter,	  also	  presented	  some	  cases	  without	  brain	  MRI	  detected	  lesions	  (17.2%).	  Not	  only	  a	  normal	  
brain	  MRI	  precludes	  a	  MS	  diagnosis,	  but	  also	  the	  absence	  of	  spinal	  cord	  lesions	  makes	  this	  an	  
improbable	  diagnosis.	  
Perhaps,	  more	  relevant	  than	  the	  presence	  or	  absence	  of	  lesions	  is	  their	  characteristics,	  which	  are	  
more	  useful	  while	  trying	  to	  rule	  in	  or	  out	  a	  diagnosis.	  In	  accordance	  to	  this:	  T1	  hypointense	  brain	  
MRI	  lesions	  were	  the	  most	  frequent	  finding	  in	  the	  MS	  group,	  while	  in	  the	  non-­‐MS	  only	  25.0%	  
patients’	  lesions	  had	  these	  signal	  characteristics;	  the	  absence	  of	  infratentorial	  lesions	  and	  
negative	  enhancement	  in	  brain	  MRI	  were	  more	  frequent	  in	  non-­‐MS	  group,	  which	  can	  
suggest/reinforce	  that	  these	  parameters	  should	  be	  also	  considered	  in	  the	  diagnosis	  process.	  
Concerning	  the	  spinal	  cord	  MRI,	  single	  lesion	  detection	  was	  a	  major	  finding	  in	  the	  non-­‐MS	  group,	  
with	  a	  75%	  reported	  frequency,	  in	  face	  of	  the	  39.3%	  of	  MS	  patients.	  Also,	  medullary	  cone	  
location	  and	  longitudinally	  extensive	  lesions	  suggested	  a	  non-­‐MS	  diagnosis	  as	  none	  MS	  patient	  
had	  lesions	  on	  that	  location	  and	  only	  one	  patient	  having	  LELs.	  Some	  of	  these	  parameters	  are	  
already	  considered	  as	  MRI	  “red	  flags”	  and,	  therefore,	  their	  presence	  should	  alert	  the	  clinician	  to	  
seek	  an	  alternative	  diagnosis	  [2].	  
	  
Cerebrospinal fluid findings 
The	  last	  revised	  McDonald	  criteria	  recognizes	  the	  value	  of	  CSF	  findings	  in	  MS	  diagnosis,	  namely	  
elevated	  IgG	  index	  or	  2	  or	  more	  OCBs.	  Positive	  findings	  support	  the	  inflammatory	  demyelinating	  
nature	  of	  the	  underlying	  conditions	  and	  can	  be	  important	  in	  alternative	  diagnosis	  evaluation	  and	  
CDMS	  prediction	  [9].	  However,	  with	  the	  recent	  simplification	  of	  DIS	  and	  DIT	  criteria,	  CSF	  positivity	  
for	  OCBs	  is	  no	  longer	  a	  validated	  tool	  in	  MS	  diagnosis	  since	  DIS	  criteria	  rely	  only	  on	  MRI.	  Our	  
records	  emphasize	  the	  supportive	  role	  of	  OCBs	  in	  MS	  diagnosis	  as,	  even	  in	  such	  a	  small	  cohort,	  
there	  is	  a	  great	  discrepancy	  between	  prevalence	  values	  of	  OCBs	  positivity	  between	  groups,	  which	  
makes	  this	  an	  important	  clinical	  practice	  tool.	  Prevalence	  of	  OCBs	  positivity	  in	  this	  cohort	  was	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only	  slighter	  lower	  than	  other	  reported	  incidences	  (CSF-­‐restricted	  OCBs	  were	  found	  in	  89%	  of	  411	  
patients	  with	  MS	  in	  Franciotta	  D	  et	  al	  (2008)	  [21]),	  with	  70%	  of	  negative	  results	  attributable	  to	  CIS	  
diagnosis.	  However,	  these	  findings	  are	  highly	  variable	  between	  reports,	  as	  different	  laboratory	  
methods	  are	  used.	  Records	  from	  serum	  OCBs	  showed	  positive	  results	  in	  only	  one	  (MS)	  patient;	  of	  
note,	  these	  were	  in	  lesser	  number	  than	  in	  CSF	  matched	  sample.	  An	  analysis	  attending	  the	  CSF-­‐
OCBs	  in	  MS	  group	  by	  age	  (patients	  with	  less	  than	  30	  years	  old	  versus	  patients	  with	  30	  or	  more	  
years	  old)	  and	  gender	  (female	  versus	  male)	  was	  also	  performed:	  positive	  results	  were	  only	  
marginally	  higher	  in	  the	  younger	  than	  30	  years	  old	  sub-­‐group	  (81.3%	  vs	  78.6%)	  and	  in	  female	  MS	  
patients	  (84.4%	  vs	  72.2%).	  Finally,	  other	  parameters	  analyzed	  that	  may	  constitute	  clinical	  clues	  
for	  diagnostic	  decision	  between	  the	  two	  compared	  groups	  are	  (i)	  the	  lower	  average	  content	  of	  
CSF	  cells	  in	  the	  MS	  group,	  (ii)	  the	  slighter	  higher	  protein	  content	  and	  (iii)	  the	  higher	  average	  IgG	  
index	  in	  this	  biologic	  fluid	  in	  the	  MS	  group.	  
	  
Imunological studies 
A	  number	  of	  neurologic	  syndromes	  may	  be	  evoked	  by	  involvement	  of	  the	  CNS	  due	  to	  systemic	  
diseases	  such	  as	  SLE,	  sarcoidosis,	  Beçhet	  disease	  and	  Sjorgren´s	  syndrome	  and	  may	  be	  
confounded	  with	  another	  chronic	  inflammatory	  diseases	  restricted	  to	  CNS,	  as	  MS	  or	  other	  non-­‐
MS	  IIDD.	  Exclusion	  of	  such	  MS	  mimics	  is	  important	  as	  immunomodulatory	  treatment	  of	  MS	  may	  
potentially	  induce	  (drug-­‐induced	  SLE)	  or	  aggravate	  lupus	  disease	  activity	  [12,	  22].	  Blood	  tests	  and	  
autoantibodies	  assays	  in	  a	  CIS	  setting	  may	  be	  helpful	  as	  they	  can	  provide	  diagnostic	  clues	  for	  
systemic	  inflammatory	  diseases.	  Although,	  a	  normal	  immunological	  status	  in	  a	  patient	  gives	  no	  
guarantee	  for	  the	  absence	  of	  collagenoses	  or	  vasculitidis	  and,	  in	  some	  cases,	  further	  
investigations	  have	  to	  be	  considered	  if	  there	  is	  uncertainty	  about	  the	  diagnosis.	  Still,	  an	  abnormal	  
immunological	  status	  doesn´t	  preclude	  a	  MS	  diagnosis:	  the	  presence	  of	  non-­‐organ-­‐specific	  
autoantibodies	  in	  sera	  of	  MS	  patients	  has	  been	  described	  (among	  others,	  ANAs	  and	  anti-­‐	  β2GPI	  
IgM)	  [23].	  Our	  study	  is	  consistent	  with	  this	  variability	  in	  the	  described	  phenotypes:	  16.7%	  of	  non-­‐
MS	  and	  13.5%	  of	  MS	  patients	  had	  a	  positive	  immunological	  study.	  In	  the	  latter	  group,	  only	  one	  
patient	  showed	  ANA	  (and	  SSa)	  positivity,	  while	  the	  6	  remaining	  patients	  were	  aPL	  (β2GPI)	  
positive.	  However,	  according	  to	  Szmyrka-­‐Kaczmarek,	  ANAs	  are	  related	  with	  a	  shorter	  disease	  
duration	  and	  a	  lower	  disability	  score,	  while	  anti-­‐β2GPI	  antibodies	  were	  more	  frequent	  in	  patients	  
with	  secondary	  progressive	  MS	  form,	  with	  a	  longer	  disease	  duration	  [23].	  Because	  auto-­‐
antibodies	  positivity	  may	  precede	  clinical	  disease	  presentation	  and	  because	  a	  neurological	  
presentation	  is	  well-­‐known,	  this	  subgroup	  would	  require	  further	  follow-­‐up.	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Conclusion 
An	  acute/subacute	  isolated	  neurological	  syndrome	  is	  a	  diagnostic	  challenge:	  it	  is	  the	  most	  
common	  presentation	  in	  MS,	  but	  it	  can	  also	  be	  the	  first	  clinical	  manifestation	  of	  other,	  CNS	  
restricted	  or	  systemic,	  diseases.	  Also,	  the	  conversion	  rate	  from	  a	  CIS	  to	  CDMS	  exhibits	  a	  great	  
variation.	  Because	  of	  different	  treatment	  strategies	  and	  because	  early	  MS	  treatment	  leads	  to	  a	  
better	  prognosis,	  it	  is	  important	  to	  distinguish	  between	  the	  different	  “MS	  mimics”.	  In	  our	  cohort,	  
a	  careful	  clinical	  history	  on	  actual/previous	  neurological/systemic	  events,	  as	  well	  as	  on	  family	  
history	  of	  neurological,	  vascular	  and	  systemic	  inflammatory	  diseases,	  provided	  some	  diagnostic	  
clues,	  although	  not	  statistically	  significant.	  Normal	  brain	  MRI	  or	  isolated	  optic	  nerve	  T2	  
hyperintensity	  were	  here	  considerable	  “red	  flags”	  and,	  once	  an	  abnormal	  brain	  MRI	  was	  
detected,	  non-­‐enhancing	  lesions	  restricted	  to	  the	  supratentorial	  area	  were	  also	  “red	  flags”,	  which	  
was	  confirmed	  by	  statistical	  analysis	  (significant	  relation	  between	  MS	  and	  lesion	  enhancement	  
was	  noted).	  Spinal	  cord	  MRI	  also	  provided	  information	  on	  final	  diagnosis:	  abnormal	  scans	  with	  a	  
single	  lesion,	  extra-­‐cervical	  lesions	  and	  longitudinally	  extensive	  lesions	  were	  less	  suggestive	  of	  a	  
MS	  diagnosis	  (the	  latter	  confirmed	  by	  statistical	  analysis).	  On	  the	  other	  hand,	  short	  segment	  T1	  
hypointense	  lesions	  with	  a	  cervical	  or	  cervical	  plus	  dorsal	  location	  pointed	  to	  a	  MS.	  Finally,	  
laboratory	  findings	  in	  MS	  group,	  as	  expected,	  showed	  a	  higher	  prevalence	  of	  positive	  OCBs	  
restricted	  to	  CSF	  (which	  revealed	  to	  be	  the	  most	  statistically	  significant	  finding	  establishing	  a	  
relation/strong	  association	  between	  MS	  and	  CSF-­‐OCB	  presence)	  and	  higher	  IgG	  index	  average,	  
with	  lower	  average	  value	  of	  CSF-­‐cells.	  In	  our	  cohort,	  a	  positive	  autoantibody	  assay	  didn’t	  
preclude	  a	  MS	  diagnosis,	  especially	  if	  the	  positive	  autoantibody	  were	  aPL.	  Neither	  clinical	  
symptoms	  nor	  additional	  analyses	  such	  as	  serological	  findings	  or	  CSF	  analyses	  are	  able	  to	  
differentiate	  between	  these	  diseases	  with	  certainty.	  Nevertheless,	  taking	  all	  findings	  together,	  an	  
early	  and	  accurate	  diagnosis	  may	  be	  possible.	  Once	  the	  diagnosis	  of	  MS	  is	  made,	  a	  careful	  follow-­‐
up	  must	  be	  provided,	  with	  regular	  re-­‐evaluations	  in	  face	  of	  unexpected	  or	  atypical	  
clinical/paraclinical	  findings.	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Tables 
Table	  1	  Demographic	  and	  clinical	  features	  at	  onset	  of	  total	  population,	  non-­‐MS	  and	  MS	  groups	  
 
	    
Characteristic Non-MS group MS group Total population 
Number of patients 30 (36.6%) 52 (63.4%) 82 (100.0%) 
Sex    
Female 20/30 (66.7%) 33/52 (63.5%) 53/82 (64.6%) 
Male 10/30 (33.3%) 19/52 (36.5%) 29/82 (35.4%) 
Female/male ratio 2/1 1.7/1 1.8/1 
Age at onset (average ± SD), years 30.8 ± 7.0 30.8 ± 6.6 30.8 ± 6.7 
Presenting symptoms    
Multifocal symptoms 1/30 (3.3%) 7/52 (13.5%) 8/82 (9.8%) 
Monofocal symptoms    
Cerebral hemispheres 5/30 (16.7%) 13/52 (25.0%) 18/82 (22.0%) 
Brain stem/cerebellum 1/30 (3.3%) 8/52 (15.4%) 9/82 (11.0%) 
Optic nerve 10/30 (33.3%) 10/52 (19.2%) 20/82 (24.4%) 
Spinal cord 9/30 (30.0%) 14/52 (26.9%) 23/82 (28.0%) 
Other symptoms 4/30 (13.3%) - 4/82 (4.9%) 
Symptoms onset    
Acute 12/30 (40.0%) 20/52 (38.5%) 32/82 (39.0%) 
Progressive 16/30 (53.3%) 31/52 (59.6%) 47/82 (57.3%) 
NA 2/30 (6.7%) 1/52 (1.92%) 3/82 (3.7%) 
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Figure Captions 
Fig.	  1	  Final	  diagnosis	  in	  eighty-­‐two	  patients	  admitted	  into	  Centro	  Hospitalar	  de	  S.	  João	  –	  EPE	  with	  
white	  matter	  lesions	  on	  MRI	  scans	  and/or	  with	  neuro-­‐inflammatory	  syndromes,	  expressed	  by	  
percentage	  of	  patients.	  IIDD,	  idiopathic	  inflammatory	  demyelinating	  disease;	  NA,	  diagnose	  not	  
performed;	  CRION,	  chronic	  relapsing	  inflammatory	  optic	  neuropathy;	  ADEM,	  acute	  disseminated	  
encephalomyelitis;	  RIS,	  radiological	  isolated	  syndrome;	  CIS,	  clinical	  isolated	  syndrome;	  CDMS,	  
clinically	  definite	  multiple	  sclerosis	  
Fig.	  2	  Clinical	  characteristics	  at	  onset	  of	  MS	  and	  non-­‐MS	  patients,	  expressed	  by	  percentage	  of	  
patients	  a.	  Fatigue	  in	  MS	  diagnosis	  b.	  Mood	  disorders	  in	  MS	  diagnosis	  c.	  Systemic	  symptoms	  in	  
MS	  diagnosis	  d.	  Family	  history	  in	  MS	  diagnosis	  
Fig.	  3	  Brain	  MRI	  characteristics	  at	  onset	  of	  MS	  and	  non-­‐MS	  patients,	  expressed	  by	  percentage	  of	  
patients	  a.	  Location	  of	  lesions	  in	  MS	  diagnosis	  b.	  T1	  hypointense	  lesions	  in	  MS	  diagnosis	  c.	  
Lesions	  enhacement	  in	  MS	  diagnosis.	  Statistical	  significance	  is	  shown,	  *P	  <	  0.01,	  Fisher's	  exact	  
test	  
Fig.	  4	  Spinal	  cord	  MRI	  characteristics	  at	  onset	  of	  MS	  and	  non-­‐MS	  patients,	  expressed	  by	  
percentage	  of	  patients	  a.	  Location	  of	  lesions	  in	  MS	  lesions	  b.	  Number	  of	  lesions	  in	  MS	  diagnosis	  c.	  
Longitudinally	  extensive	  lesions	  (LELs)	  in	  MS	  diagnosis.	  NA,	  data	  not	  available	  for	  this	  analysis.	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Supplementary Material 
Supplementary Table 1 CIS clinical features and likelihood of signaling an MS diagnosis [2] 
 
Supplementary Table 2 Differential diagnosis for the central nervous system lesions disseminated 
in space and time [10] 
Type Disease 
Inflammatory MS, NMO, ADEM, ITM, SLE, Sjogren syndrome, Behçet´s disease, neurosarcoidosis, Wegener´s granulomatosis, CNS vasculitis, Susac´s syndrome 
Infectious HIV, HTLV, neurosyphilis, PML, neuroborreliosis, Whipple´s disease 
Metabolic Vitamin B12 deficiency, porphyria 
Degenerative Mitochondrial encephalomyopathy, hereditary spastic para-paresis, Fabry´s disease, leukodystrophies 
Vascular CADASIL, anti-phospholipid antibody syndrome, multiple emboli, small vessel disease, migrane 
Neoplastic Metastases, lymphoma 
CIS typically seen in MS Less common CIS features which may be seen in MS 
Atypical CIS features not expected 
in MS 
Optic nerve 
Unilateral optic neuritis Bilateral simultaneous optic neuritis Progressive, optic neuropathy 
Pain on eye movement No pain Severe, continuous orbital pain 
Partial and mainly central visual 
blurring 
No light perception Persistent complete loss of vision 
Normal disk or mild disk swelling Moderate to severe disc swelling with 
no hemorrhages 
Neuroretinitis (optic disk swelling 
with macular star) 





ophthalmoplegia, facial palsy, facial 
myokymia 
Complete external 
ophthalmoplegia; vertical gaze 
palsies 
Ataxia and multidirectional 
nystagmus 
Deafness Vascular territory syndrome, e.g., 
lateral medullary 
Sixth nerve palsy One-and-a-half syndrome Third nerve palsy 
Facial numbness Trigeminal neuralgia Progressive trigeminal sensory 
neuropathy 
 Paroxysmal tonic spasms Focal dystonia, torticollis 
Spinal cord 
Partial myelopathy Complete transverse myelitis Anterior spinal artery territory 
lesion (sparing posterior columns 
only) 
Lhermitte´s symptom Radiculopathy, areflexia Cauda equine syndrome 
Deafferented hand Segmental loss of pain and temperature 
sensation 
Sharp sensory level to all 
modalities and localized spinal 
pain 
Numbness Partial Brown-Sequard syndrome 
(sparing posterior columns) 
Complete Brown-Sequard 
syndrome 
Urinary urgency, incontinence, 
erectile dysfunction 
Faecal incontinence Acute urinary retention 
Progressive spastic paraplegia 
(asymmetrical) 
Progressive spastic paraplegia 
(symmetrical) 
Progressive sensory ataxia 
(posterior columns) 
Cerebral hemispheres 
Mild subcortical cognitive 
impairment 
Epilepsy Encephalopathy (obtundation, 
confusion, drowsiness) 
Hemiparesis Hemianopia Cortical blindness 
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Age/Sex Clinical presentation Other presenting/past symptoms CSF findings Blood analysis/other diagnostic procedures Final diagnosis 
24/M Optic nerve - Cells ESR Optic neuritis, idiopathic  
40/F Other Recent infection Proteins - RIS 
35/M Cerebral hemispheres Recent infection HHV6 (+) Anemia; Neutrophilia; ESR; CPR ADEM 
22/F Optic nerve - IgG Index - Optic neuritis, idiopathic  
36/M Brain stem Recent infection; Ulcers Proteins; Neutrophils Neutrophilia; CPR ADEM 
21/M Optic nerve Recent infection; Reumathologic symptoms Proteins; Cells; OCBs (+) - Optic neuritis, idiopathic  
25/F Spinal cord - OCBs (+) Anemia NA IIDD 
20/F Multifocal symptoms - Proteins ESR CRION 
36/F Other - IgG Index ESR RIS 
24/F Optic nerve - Proteins Leukocitosis Optic neuritis, idiopathic  
33/M Cerebral hemispheres - - Trombocytopenia Leukodystrophy with axonal spheroids 
38/F Spinal cord Recent infection - - Acute myelitis, parainfectious 
29/F Other - - β2GPI (+) RIS 
27/F Optic nerve Recent infection Lymphocytes; IgG Index; OCBs (+) ANA (+) Inflammatory disease 
26/F Cerebral hemispheres - EBV (+) ANA (+) Inflammatory disease 
42/F Spinal cord - - - Acute myelitis, idiopathic 
30/F Spinal cord - Proteins; Lymphocytes; IgG Index; OCBs (+) - Acute myelitis, idiopathic 
34/F Optic nerve - Proteins; Mononuclear cells; M. pneumoniae (+) 
Anemia; ESR; CPR; abnormal CXR; 
abnormal adenopathy biopsy 
Type 1 pulmonary sarcoidosis; 
Neurossarcoidosis 
24/F Cerebral hemispheres Fatigue; Ulcers; Reumathological symptoms; Rash Proteins; Lymphocytes; OCBs (+) Low vit B12; anti-PR3 (+); β2GPI (+) Neurolupus 
36/M Spinal cord - - Macrocytosis; low vit B12 Subacute combined degeneration of spinal cord 
23/F Optic nerve - - - Inflammatory disease 
33/M Spinal cord Recent infection Proteins; Mononuclear cells Anemia; trombocytopenia; ESR ADEM 
36/M Cerebral hemispheres Fatigue Proteins CPR; ANA (+) Primary CNS vasculitis 
26/F Other - Proteins Trombocytosis; ESR RIS 
44/M Spinal cord - Proteins; Lymphocytes; CMV (+) - Acute myelitis, parainfectious 
31/M Spinal cord - IgG Index; Enterovirus (+) Neutrophilia; CPR Acute myelitis, parainfectious 
20/F Optic nerve Recent infection; Ulcers Proteins; IgG Index; Enterovirus (+) HLAB51 (-); pathergy test (+); abnormal oral ulcer biopsy Neurobeçhet 
40/F Optic nerve - Proteins - NA IIDD 
35/F Spinal cord - IgG Index; OCBs (+) - Acute myelitis, idiopathic 
35/F Optic nerve - Proteins ESR Inflammatory disease 
4 
Recent infection, systemic inflammatory symptoms/signs in previous 3 months; reumathologic symptoms, arthritis, polyarthalgias, myalgias included; ESR, erythrocyte 
sedimentation rate; CRP, C-reactive protein; ANA, antinuclear antibody; β2GPI, anti-β2 glicoprotein I antibodies; CXR, chest X-ray; OCB (+), oligoclonal bands in 
cerebrospinal fluid; IIDD, idiopathic inflammatory demyelinating disease; NA IIDD, diagnose not performed on an IIDD; CRION, chronic relapsing inflammatory optic 
neuropathy; ADEM, acute disseminated encephalomyelitis; RIS, radiological isolated syndrome 
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Age/Sex Clinical presentation Other presenting/past symptoms CSF findings Blood analysis/other diagnostic procedures Final diagnosis 
32/F Multifocal symptoms Fatigue IgG Index; OCBs (+) - MS, relapse remitting 
41/F Spinal cord Fatigue Protein; IgG Index; OCBs (+) β2GPI (+) MS, relapse remitting 
19/F Cerebral hemispheres - Cells - CIS 
38/F Spinal cord Fatigue; SICCA/Ulcers IgG Index; OCBs (+) ESR MS, relapse remitting 
21/M Spinal cord - Protein; OCBs (+) β2GPI (+) CIS 
40/F Spinal cord - OCBs (+) - MS, primary progressive 
30/F Optic nerve - OCBs (+) - MS, relapse remitting 
28/M Brain stem - Cells; IgG Index; OCBs (+) - CIS 
34/M Optic nerve - Protein; IgG Index; OCBs (+) - MS, relapse remitting 
23/M Spinal cord - - ANA (+);anti- SSa (+) CIS 
36/F Spinal cord - OCBs (+) - CIS 
22/F Cerebral hemispheres - IgG Index; OCBs (+) Neutropenia; ESR CIS 
32/M Brain stem - - - CIS 
24/F Cerebral hemispheres - IgG Index; OCBs (+) - MS, relapse remitting 
23/F Multifocal symptoms - Protein; IgG Index; OCBs (+) ESR and CRP MS, relapse remitting 
27/M Brain stem Fatigue IgG Index; OCBs (+); Enterovirus (+) - CIS 
29/M Spinal cord - Protein; Cells; IgG Index; OCBs (+) - CIS 
28/F Cerebral hemispheres - Protein; IgG Index - CIS 
23/F Optic nerve - OCBs (+) - CIS 
38/F Optic nerve Fatigue OCBs (+) - MS, relapse remitting 
24/M Spinal cord - IgG Index; OCBs (+) - MS, relapse remitting 
40/M Cerebral hemispheres Recent infection Protein - MS 
19/F Multifocal symptoms - Protein; IgG Index; OCBs (+) - CIS 
35/M Cerebral hemispheres - OCBs (+) - MS, relapse remitting 
37/F Optic nerve - IgG Index; OCBs (+) - CIS 
40/F Multifocal symptoms - Cells; IgG Index; OCBs (+) - MS, relapse remitting 
33/F Brain stem Recent infection OCBs (+) - CIS 
30/F Multifocal symptoms - Protein; IgG Index; OCBs (+) - MS, pseudotumoral 
40/F Brain stem - Protein; IgG Index; OCBs (+) - MS, relapse remitting 
27/F Cerebral hemispheres - IgG Index; OCBs (+) - MS, relapse remitting 
22/F Multifocal symptoms Recent infection IgG Index ESR MS, relapse remitting 
27/F Optic nerve - Protein - CIS 
31/M Spinal cord - Protein; IgG Index; ESR CIS 
23/M Optic nerve - Protein; Cells; OCBs (+) - CIS 
27/M Multifocal symptoms - Protein; IgG Index; OCBs (+) - MS, relapse remitting 
30/M Cerebral hemispheres Recent infection Protein; IgG Index; Anemia; ESR CIS 
36/F Brain stem Fatigue; Reumathologic symptoms - - CIS 
26/F Cerebral hemispheres Recent infection Protein; IgG Index; OCBs (+) - CIS 
36/F Brain stem - Protein; Cells ESR; β2GPI (+) MS, relapse remitting 
37/M Optic nerve - Protein β2GPI (+) CIS 
19/F Cerebral hemispheres Recent infection Protein; IgG Index; OCBs (+); M. pneumoniae (+) Low vit B9 CIS 
27/F Cerebral hemispheres Rash Protein; Cells; IgG Index; OCBs (+) CRP MS, relapse remitting 
38/F Cerebral hemispheres - Protein; OCBs (+) - MS, relapse remitting 
27/M Spinal cord - Protein; Cells; IgG Index; OCBs (+) - CIS 
40/M Optic nerve - Protein; Cells; OCBs (+) - CIS 
32/M Spinal cord - Protein; IgG Index; OCBs (+) - MS, relapse remitting 
37/F Spinal cord Fatigue Protein; IgG Index; OCBs (+) - MS, relapse remitting 
31/F Brain stem Ulcers Protein; IgG Index; OCBs (+) aCL (+); β2GPI (+) CIS 
36/F Cerebral hemispheres Fatigue IgG Index; OCBs (+) - MS, relapse remitting 
27/F Optic nerve Recent infection Protein; OCBs (+) CRP CIS 
40/F Spinal cord - OCBs (+) β2GPI (+) CIS 
38/M Spinal cord - Protein; IgG Index; OCBs (+) - MS, relapse remitting 
6 
Recent infection, systemic inflammatory symptoms/signs in previous 3 months; reumathologic symptoms, arthritis, polyarthalgias, myalgias included; ESR, erythrocyte 
sedimentation rate; CRP, C-reactive protein; ANA, antinuclear antibody; β2GPI, anti-β2 glicoprotein I antibodies; aCL, anticardiolipin antibodies; OCB (+), oligoclonal bands in 
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Papers must be written in English.
Papers must not exceed 8 printed pages (20 type-written pages of 32 lines each) plus 8
figures, taking up no more than 3 printed pages altogether. Exception to this rule can be
made only with the agreement of the Joint Chief Editors.
Letters to the Editors will be considered for publications of brief communications or case




Submission of a manuscript implies: that the work described has not been published before; that it is not
under consideration for publication anywhere else; that its publication has been approved by all co-
authors, if any, as well as by the responsible authorities – tacitly or explicitly – at the institute where the
work has been carried out. The publisher will not be held legally responsible should there be any claims
for compensation.
Permissions
Authors wishing to include figures, tables, or text passages that have already been published elsewhere
are required to obtain permission from the copyright owner(s) for both the print and online format and to
include evidence that such permission has been granted when submitting their papers. Any material
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Word template (zip, 154 kB)
LaTeX macro package (zip, 182 kB)
Authors should submit their manuscripts online. Electronic submission substantially reduces the editorial
processing and reviewing times and shortens overall publication times. Please follow the hyperlink




The title page should include:
The name(s) of the author(s)
A concise and informative title
The affiliation(s) and address(es) of the author(s)
The e-mail address, telephone and fax numbers of the corresponding author
Abstract
Please provide an abstract of 150 to 250 words. The abstract should not contain any undefined
abbreviations or unspecified references.
Keywords
Please provide 4 to 6 keywords which can be used for indexing purposes.
TEXT
Text Formatting
Manuscripts should be submitted in Word.
Use a normal, plain font (e.g., 10-point Times Roman) for text.
Use italics for emphasis.
Use the automatic page numbering function to number the pages.
Do not use field functions.
Use tab stops or other commands for indents, not the space bar.
Use the table function, not spreadsheets, to make tables.
Use the equation editor or MathType for equations.
Save your file in docx format (Word 2007 or higher) or doc format (older Word versions).
Manuscripts with mathematical content can also be submitted in LaTeX.
Headings
Please use no more than three levels of displayed headings.
Abbreviations
Abbreviations should be defined at first mention and used consistently thereafter.
Footnotes
Footnotes can be used to give additional information, which may include the citation of a reference
included in the reference list. They should not consist solely of a reference citation, and they should
never include the bibliographic details of a reference. They should also not contain any figures or tables.
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Footnotes to the text are numbered consecutively; those to tables should be indicated by superscript
lower-case letters (or asterisks for significance values and other statistical data). Footnotes to the title or
the authors of the article are not given reference symbols.
Always use footnotes instead of endnotes.
Acknowledgments
Acknowledgments of people, grants, funds, etc. should be placed in a separate section before the
reference list. The names of funding organizations should be written in full.
SCIENTIFIC STYLE
Generic names of drugs and pesticides are preferred; if trade names are used, the generic name should
be given at first mention.
REFERENCES
Citation
Reference citations in the text should be identified by numbers in square brackets. Some examples:
1. Negotiation research spans many disciplines [3].
2. This result was later contradicted by Becker and Seligman [5].
3. This effect has been widely studied [1-3, 7].
Reference list
The list of references should only include works that are cited in the text and that have been published or
accepted for publication. Personal communications and unpublished works should only be mentioned in
the text. Do not use footnotes or endnotes as a substitute for a reference list.
The entries in the list should be numbered consecutively.
Journal article
Gamelin FX, Baquet G, Berthoin S, Thevenet D, Nourry C, Nottin S, Bosquet L (2009) Effect
of high intensity intermittent training on heart rate variability in prepubescent children. Eur J
Appl Physiol 105:731-738. doi: 10.1007/s00421-008-0955-8
Ideally, the names of all authors should be provided, but the usage of “et al” in long author
lists will also be accepted:
Smith J, Jones M Jr, Houghton L et al (1999) Future of health insurance. N Engl J Med
965:325–329
Article by DOI
Slifka MK, Whitton JL (2000) Clinical implications of dysregulated cytokine production. J Mol
Med. doi:10.1007/s001090000086
Book
South J, Blass B (2001) The future of modern genomics. Blackwell, London
Book chapter
Brown B, Aaron M (2001) The politics of nature. In: Smith J (ed) The rise of modern
genomics, 3rd edn. Wiley, New York, pp 230-257
Online document
Cartwright J (2007) Big stars have weather too. IOP Publishing PhysicsWeb.
http://physicsweb.org/articles/news/11/6/16/1. Accessed 26 June 2007
Dissertation
Trent JW (1975) Experimental acute renal failure. Dissertation, University of California
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EndNote style (zip, 2 kB)
Always use the standard abbreviation of a journal’s name according to the ISSN List of Title Word
Abbreviations, see
www.issn.org/2-22661-LTWA-online.php
For authors using EndNote, Springer provides an output style that supports the formatting of in-text
citations and reference list.
Authors preparing their manuscript in LaTeX can use the bibtex file spbasic.bst which is included in
Springer’s LaTeX macro package.
TABLES
All tables are to be numbered using Arabic numerals.
Tables should always be cited in text in consecutive numerical order.
For each table, please supply a table caption (title) explaining the components of the table.
Identify any previously published material by giving the original source in the form of a
reference at the end of the table caption.
Footnotes to tables should be indicated by superscript lower-case letters (or asterisks for
significance values and other statistical data) and included beneath the table body.
ARTWORK AND ILLUSTRATIONS GUIDELINES
For the best quality final product, it is highly recommended that you submit all of your artwork –
photographs, line drawings, etc. – in an electronic format. Your art will then be produced to the highest
standards with the greatest accuracy to detail. The published work will directly reflect the quality of the
artwork provided.
Electronic Figure Submission
Supply all figures electronically.
Indicate what graphics program was used to create the artwork.
For vector graphics, the preferred format is EPS; for halftones, please use TIFF format. MS
Office files are also acceptable.
Vector graphics containing fonts must have the fonts embedded in the files.
Name your figure files with "Fig" and the figure number, e.g., Fig1.eps.
Line Art
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Definition: Black and white graphic with no shading.
Do not use faint lines and/or lettering and check that all lines and lettering within the figures
are legible at final size.
All lines should be at least 0.1 mm (0.3 pt) wide.
Scanned line drawings and line drawings in bitmap format should have a minimum resolution
of 1200 dpi.
Vector graphics containing fonts must have the fonts embedded in the files.
Halftone Art
Definition: Photographs, drawings, or paintings with fine shading,
etc.
If any magnification is used in the photographs, indicate this by
using scale bars within the figures themselves.
Halftones should have a minimum resolution of 300 dpi.
Combination Art
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Combination Art
Definition: a combination of halftone and line art, e.g., halftones containing line drawing,
extensive lettering, color diagrams, etc.
Combination artwork should have a minimum resolution of 600 dpi.
Color Art
Color art is free of charge for online publication.
If black and white will be shown in the print version, make sure that the main information will
still be visible. Many colors are not distinguishable from one another when converted to black
and white. A simple way to check this is to make a xerographic copy to see if the necessary
distinctions between the different colors are still apparent.
If the figures will be printed in black and white, do not refer to color in the captions.
Color illustrations should be submitted as RGB (8 bits per channel).
Figure Lettering
To add lettering, it is best to use Helvetica or Arial (sans serif fonts).
Keep lettering consistently sized throughout your final-sized artwork, usually about 2–3 mm
(8–12 pt).
Variance of type size within an illustration should be minimal, e.g., do not use 8-pt type on an
axis and 20-pt type for the axis label.
Avoid effects such as shading, outline letters, etc.
Do not include titles or captions within your illustrations.
Figure Numbering
All figures are to be numbered using Arabic numerals.
Figures should always be cited in text in consecutive numerical order.
Figure parts should be denoted by lowercase letters (a, b, c, etc.).
If an appendix appears in your article and it contains one or more figures, continue the
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If an appendix appears in your article and it contains one or more figures, continue the
consecutive numbering of the main text. Do not number the appendix figures, "A1, A2, A3,
etc." Figures in online appendices (Electronic Supplementary Material) should, however, be
numbered separately.
Figure Captions
Each figure should have a concise caption describing accurately what the figure depicts.
Include the captions in the text file of the manuscript, not in the figure file.
Figure captions begin with the term Fig. in bold type, followed by the figure number, also in
bold type.
No punctuation is to be included after the number, nor is any punctuation to be placed at the
end of the caption.
Identify all elements found in the figure in the figure caption; and use boxes, circles, etc., as
coordinate points in graphs.
Identify previously published material by giving the original source in the form of a reference
citation at the end of the figure caption.
Figure Placement and Size
When preparing your figures, size figures to fit in the column width.
For most journals the figures should be 39 mm, 84 mm, 129 mm, or 174 mm wide and not
higher than 234 mm.
For books and book-sized journals, the figures should be 80 mm or 122 mm wide and not
higher than 198 mm.
Permissions
If you include figures that have already been published elsewhere, you must obtain permission from the
copyright owner(s) for both the print and online format. Please be aware that some publishers do not
grant electronic rights for free and that Springer will not be able to refund any costs that may have
occurred to receive these permissions. In such cases, material from other sources should be used.
Accessibility
In order to give people of all abilities and disabilities access to the content of your figures, please make
sure that
All figures have descriptive captions (blind users could then use a text-to-speech software or
a text-to-Braille hardware)
Patterns are used instead of or in addition to colors for conveying information (color-blind
users would then be able to distinguish the visual elements)
Any figure lettering has a contrast ratio of at least 4.5:1
ELECTRONIC SUPPLEMENTARY MATERIAL
Springer accepts electronic multimedia files (animations, movies, audio, etc.) and other supplementary
files to be published online along with an article or a book chapter. This feature can add dimension to the
author's article, as certain information cannot be printed or is more convenient in electronic form.
Submission
Supply all supplementary material in standard file formats.
Please include in each file the following information: article title, journal name, author names;
affiliation and e-mail address of the corresponding author.
To accommodate user downloads, please keep in mind that larger-sized files may require
very long download times and that some users may experience other problems during
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very long download times and that some users may experience other problems during
downloading.
Audio, Video, and Animations
Always use MPEG-1 (.mpg) format.
Text and Presentations
Submit your material in PDF format; .doc or .ppt files are not suitable for long-term viability.
A collection of figures may also be combined in a PDF file.
Spreadsheets
Spreadsheets should be converted to PDF if no interaction with the data is intended.
If the readers should be encouraged to make their own calculations, spreadsheets should be
submitted as .xls files (MS Excel).
Specialized Formats
Specialized format such as .pdb (chemical), .wrl (VRML), .nb (Mathematica notebook), and
.tex can also be supplied.
Collecting Multiple Files
It is possible to collect multiple files in a .zip or .gz file.
Numbering
If supplying any supplementary material, the text must make specific mention of the material
as a citation, similar to that of figures and tables.
Refer to the supplementary files as “Online Resource”, e.g., "... as shown in the animation
(Online Resource 3)", “... additional data are given in Online Resource 4”.
Name the files consecutively, e.g. “ESM_3.mpg”, “ESM_4.pdf”.
Captions
For each supplementary material, please supply a concise caption describing the content of
the file.
Processing of supplementary files
Electronic supplementary material will be published as received from the author without any
conversion, editing, or reformatting.
Accessibility
In order to give people of all abilities and disabilities access to the content of your supplementary files,
please make sure that
The manuscript contains a descriptive caption for each supplementary material
Video files do not contain anything that flashes more than three times per second (so that
users prone to seizures caused by such effects are not put at risk)
INTEGRITY OF RESEARCH AND REPORTING
Ethical standards
Manuscripts submitted for publication must contain a statement to the effect that all human studies have
been approved by the appropriate ethics committee and have therefore been performed in accordance
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Ethical Standards Agreement Form (pdf, 49 kB)
Conflict of Interest Statement (pdf, 33 kB)
with the ethical standards laid down in the 1964 Declaration of Helsinki. It should also be stated clearly in
the text that all persons gave their informed consent prior to their inclusion in the study. Details that
might disclose the identity of the subjects under study should be omitted.
The editors reserve the right to reject manuscripts that do not comply with the above-mentioned
requirements. The author will be held responsible for false statements or failure to fulfill the above-
mentioned requirements.
Conflict of interest
Authors must indicate whether or not they have a financial relationship with the organization that
sponsored the research. This note should be added in a separate section before the reference list.
If no conflict exists, authors should state: The authors declare that they have no conflict of interest.
Both statements have also to be sent to the Editor-in-Chief together with the original manuscript when
this is submitted. The forms can be downloaded at the end of this paragraph.
They have to be filled-in, printed, signed, scanned and uploaded as “Supplementary Material” to the
original manuscript files.
DOES SPRINGER PROVIDE ENGLISH LANGUAGE SUPPORT?
Manuscripts that are accepted for publication will be checked by our copyeditors for spelling and formal
style. This may not be sufficient if English is not your native language and substantial editing would be
required. In that case, you may want to have your manuscript edited by a native speaker prior to
submission. A clear and concise language will help editors and reviewers concentrate on the scientific
content of your paper and thus smooth the peer review process.
The following editing service provides language editing for scientific articles in:
Medicine, biomedical and life sciences, chemistry, physics, engineering, business/economics, and
humanities
Edanz Editing Global
Use of an editing service is neither a requirement nor a guarantee of acceptance for publication.
Please contact the editing service directly to make arrangements for editing and payment.
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Upon acceptance of your article you will receive a link to the special Author Query Application at
Springer’s web page where you can sign the Copyright Transfer Statement online and indicate whether
you wish to order OpenChoice and offprints.
Once the Author Query Application has been completed, your article will be processed and you will
receive the proofs.
Open Choice
In addition to the normal publication process (whereby an article is submitted to the journal and access
to that article is granted to customers who have purchased a subscription), Springer now provides an
alternative publishing option: Springer Open Choice. A Springer Open Choice article receives all the
benefits of a regular subscription-based article, but in addition is made available publicly through
Springer’s online platform SpringerLink.
Springer Open Choice
Copyright transfer
Authors will be asked to transfer copyright of the article to the Publisher (or grant the Publisher exclusive
publication and dissemination rights). This will ensure the widest possible protection and dissemination
of information under copyright laws.
Open Choice articles do not require transfer of copyright as the copyright remains with the author. In
opting for open access, the author(s) agree to publish the article under the Creative Commons
Attribution License.
Offprints
Offprints can be ordered by the corresponding author.
Color illustrations
Publication of color illustrations is free of charge.
Proof reading
The purpose of the proof is to check for typesetting or conversion errors and the completeness and
accuracy of the text, tables and figures. Substantial changes in content, e.g., new results, corrected
values, title and authorship, are not allowed without the approval of the Editor.
After online publication, further changes can only be made in the form of an Erratum, which will be
hyperlinked to the article.
Online First
The article will be published online after receipt of the corrected proofs. This is the official first publication
citable with the DOI. After release of the printed version, the paper can also be cited by issue and page
numbers.
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